CNS Pharmaceuticals (CNSP) Fundamental Analysis: Revenue, Earnings & Valuation

1.35 / 10

Underperform

Fundamental score is 1.35/10, rated Underperform. Inventory turnover (53) and interest coverage (65) are decent, but cost of sales (71.9%), full liabilities (100%) and long‑term debt ratio (6.46) are high. Revenue growth is strong yet overall metrics are weak.

Analysis Checks(4/7)

Total operating revenue (YoY growth rate %)

Value123.10

Score2/3

Weight-0.86%

1M Return0.13%

Inventory turnover ratio

Value53.12

Score2/3

Weight7.13%

1M Return-1.18%

Current liabilities / Total liabilities (%)

Value100.00

Score0/3

Weight26.44%

1M Return-4.96%

Long-term debt to working capital ratio (%)

Value6.46

Score0/3

Weight27.18%

1M Return-4.75%

Interest coverage ratio (EBIT / Interest expense) (%)

Value65.69

Score2/3

Weight7.25%

1M Return-1.17%

Operating revenue (YoY growth rate %)

Value138.18

Score0/3

Weight26.00%

1M Return-4.63%

Cost of sales ratio (%)

Value71.87

Score2/3

Weight6.86%

1M Return-1.13%

Is CNSP undervalued or overvalued?

CNSP scores 1.35/10 on fundamentals and holds a Premium valuation at present. Backed by its -296.30% ROE, 0.00% net margin, -0.12 P/E ratio, 0.41 P/B ratio, and 92.34% earnings growth, these metrics solidify its Underperform investment rating.